使用医疗补助福利的合并物质相关障碍的精神分裂症患者中，棕榈酸帕利哌酮与口服非典型抗精神病药物相比的真实世界依从性和经济结果。
Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
作者信息
Joshi Kruti, Lafeuille Marie-Hélène, Kamstra Rhiannon, Tiggelaar Sean, Lefebvre Patrick, Kim Edward, Yue Yong, Tandon Neeta
机构信息
Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, USA.
Groupe d'analyse, Ltée, 1000 De La Gauchetière Ouest, Bureau 1200, Montréal, QC, Canada.
出版信息
J Comp Eff Res. 2018 Feb;7(2):121-133. doi: 10.2217/cer-2017-0043. Epub 2017 Aug 15.
AIM
Compare medication utilization, costs and healthcare resource use in schizophrenia patients with substance-related disorders initiated on once-monthly paliperidone palmitate (PP1M) or an oral atypical antipsychotic (OAA).
MATERIALS & METHODS: Data from six Medicaid states (07/2009-03/2015) were used to compare outcomes between PP1M and OAA patients.
RESULTS
PP1M patients had higher 12-month antipsychotic adherence and persistence than OAA patients. PP1M patients had lower medical (mean monthly cost difference [MMCD] = US$-191, p = 0.020), higher pharmacy (MMCD = US$250, p < 0.001) and similar total costs (MMCD = US$59, p = 0.517) during the overall follow-up. PP1M patients had lower rates of outpatient visits and inpatient days but higher rates of mental health-related utilization.
CONCLUSION
PP1M was associated with higher antipsychotic adherence and persistence, and similar total costs versus OAA.
目的
比较起始使用每月一次棕榈酸帕利哌酮（PP1M）或口服非典型抗精神病药物（OAA）的合并物质相关障碍的精神分裂症患者的药物使用情况、成本和医疗资源利用情况。
材料与方法
使用来自六个医疗补助州（2009年7月 - 2015年3月）的数据来比较PP1M组和OAA组患者的结局。
结果
PP1M组患者的12个月抗精神病药物依从性和持续性高于OAA组患者。在整个随访期间，PP1M组患者的医疗费用较低（平均每月费用差异[MMCD] = -191美元，p = 0.020），药房费用较高（MMCD = 250美元，p < 0.001），总费用相似（MMCD = 59美元，p = 0.517）。PP1M组患者的门诊就诊率和住院天数较低，但与心理健康相关的利用率较高。
结论
与OAA相比，PP1M与更高的抗精神病药物依从性和持续性以及相似的总费用相关。
Zotero 插件